We studied the clinical resistance to acyclovir of infections with varicella-zoster viruses (VZV) in patients with acquired immunodeficiency syndrome, and we correlated it to virologic analyses. Eleven patients with VZV infections (treated with acyclovir, 30 mg/kg/day, given intravenously, or 4 g/day, given orally) were included in the study because of the failure of 10 days of acyclovir therapy. Susceptibility of VZV isolates to acyclovir was tested using a plaque reduction assay to determine the 50% inhibitory concentration (IC 50 ) of acyclovir and the SI 50 (IC 50 of the patient isolate/IC 50 of the reference strain) to acyclovir. The thymidine kinase (TK) gene, which supports the resistance, was sequenced on amplified products. Only 3 patients had a significant increase in the IC 50 , as compared with the IC 50 of the reference strain (SI 50 of у4), and a mutation in the TK gene. For the other 8 patients, the clinical resistance was not confirmed by the virologic results: the SI 50 was !4, and no mutation was detected in the TK gene. Because no acyclovir-resistant strain appeared during a shorter period of time, we suggest an increase in the duration of the treatment to 21 days before acyclovir resistance is suspected.
m 2 per day [1, 2] , or orally, at 800 mg 5 times per day [1, 3, 4] . Acyclovir-resistant VZV infections are defined by the occurrence of persistent lesions after 10 days of acyclovir therapy [5, 6] . Since the first case was reported by Pawha et al. [7] in 1988, only 35 cases of infections with acyclovir-resistant strains have been described in the literature. The main risk in profoundly immunocompromised patients is visceral dissemination, especially in a neurological location. Acyclovir-resistant VZV infections have a poor prognosis, with nearly all patients dying within 6 months of diagnosis [5, [7] [8] [9] [10] [11] . The genetic support of acyclovir resistance is often a single mutation in the viral thymidine kinase (TK) gene, which is required to phosphorylate acyclovir to acyclovir monophosphate. The second and third phosphorylations leading to the active form of acyclovir are performed by cellular thymidine kinase. Point muta- tions are located anywhere within the TK gene. Inside the putative functional sites (an adenosine triphosphate-binding site and nucleotide-binding site), mutations consist of a single amino acid substitution; however, outside of these sites, mutations consist more often of a premature "codon stop" occurrence [12, 13] . In vitro acyclovir resistance is usually correlated with clinical resistance, except in a few cases [8, 12] . We conducted a retrospective study of 11 cases in which clinical VZV infections were clinically resistant to acyclovir, and we analyzed the correlation between clinical data and the virologic results.
MATERIALS AND METHODS
Patients. Inclusion criteria consisted of clinical acyclovir resistance, which was defined by the appearance of persistent lesions despite receipt of acyclovir therapy (130 mg/kg/day; 1 patient received 4 g/day) for at least 10 days, on the basis of the previously reported definition of acyclovir resistance [5, 6] . The clinical information was collected by means of medical observations provided from several medical centers (Pitié-Salpetrière Hospital, Paris; Bordeaux Hospital, Bordeaux; Ambroise Paré Hospital, Boulogne; and Necker-Enfants Malades Hospital, Paris). Eleven patients were selected. The main clinical features are summarized in table 1. Exclusion criteria consisted of receipt of inappropriate therapy (less than 10 days or 30 mg/ kg of acyclovir per day) and the lack of VZV isolation in the cutaneous lesions.
VZV isolates. VZV samples were obtained and submitted to the Virology Department at La Pitie-Salpêtrière Hospital (considered to be a reference laboratory for herpesviruses) to have an in vitro acyclovir susceptibility assay performed when acyclovir therapy had failed. For each patient, only 1 isolate, which had been obtained when acyclovir resistance occurred, was available. VZV isolates were obtained after inoculation on fibroblastic cells (MRC-5). The presence of VZV infection was recognized by its typical cytopathic effect on MRC-5 cells. Two susceptible strains were used as references: either Oka (vaccine strain) or our laboratory reference strain, Cha, which was obtained from a child with chicken pox who had never received acyclovir.
Antiviral susceptibility assay. Susceptibility of VZV to acyclovir was evaluated by the determination of the concentration of acyclovir that reduces viral replication by 50% (IC 50 ) using the late antigen reduction assay [14] . In brief, this assay was performed with different dilutions of the cell-associated virus cultivated with different antiviral concentrations; 48 h after the infection, a reduction in the synthesis of VZV late antigen was detected by immunoperoxidase staining with specific antibodies. Foci were counted under an optical microscope. IC 50 was determined as described elsewhere [14] . The test was performed-generally in duplicate, but for 2 of the 11 patients (patients 5 and 7), it was performed only once-and compared with a susceptible reference strain that was analyzed in the same experiment. According to data published elsewhere [7, 8, 10, [12] [13] [14] [15] , we selected a susceptibility index (SI 50 ; IC 50 patient isolate/IC 50 reference isolate) of у4 as the threshold to screen resistant and susceptible VZV isolates. SI 50 was calculated to avoid variability among the different methods of susceptibility determination and among the different experiments performed with the same method.
TK gene amplification and sequencing. To amplify the TK gene (1023 bp) and adjacent sequence, we used the PCR assay (primers and protocol) described elsewhere by Lacey et al. [16] in 1991. To optimize the efficiency, 3 parameters were modified: the use of the Biometra thermocycler (Biotron) with the number of cycles reduced from 60 to 40 and the last step of elongation increased to 10 min.
The main 1181-bp PCR product obtained was then purified using the Wizard PCR preps kit (Promega), except for the PCR product for patients 1 and 11, which had been studied elsewhere [14, 17] . The DNA sequencing was performed on both strands by a company that uses the dye terminator assay and the ABI sequencer (PE Applied Biosystems), except in patient 1, who has been described elsewhere [14] . The DNA sequence was analyzed using the software sequence navigator, and each patient's TK gene was compared with the TK gene of the Dumas strain, the first acyclovir-susceptible strain described in the literature [18] .
RESULTS
Ten of 11 patients selected had previously received treatment with acyclovir for at least 10 days (table 1) . For patient 8, no data were available regarding the treatment of his initial zoster, but it was typical to treat all cases of VZV infection in patients with HIV. This prior treatment had been administrated either punctually or in the long term for herpes recurrence or for anterior herpes zoster before suspicion of VZV resistance to acyclovir. Among the 11 patients, 4 had herpes zoster eruption with the usual aspects, and 7 had hyperkeratotic, crusted, and ulcerated lesions, which are often limited to 3 or 4 lesions. The mean lymphocyte CD4 ϩ cell count was cells/L (range, 6 45 ϫ 10 cells/L), and the median lymphocyte CD4 ϩ cell 6 1-290 ϫ 10 count was cells/L. The duration of the acyclovir treat- 6 10 ϫ 10 ment ranged from 10 days to several months (median duration of acyclovir therapy, 18 days). For at least 4 patients (data were unknown for patient 5), acyclovir therapy was continued, either intravenously or orally, and led to healing (complete for 3 patients and partial for patient 7) of the lesions. For the 6 other patients, the alternative antiviral drugs of foscarnet or sorivudine were introduced (table 1). Results of the phenotypic study are summarized in table 2. IC 50 and SI 50 values were between 10 mM and 155 mM and !1 and 13, respectively. Three of 11 patients had an SI 50 of у4 (the IC 50 values were 1100 mM, 23 mM, and 155 mM for patients 1, 2, and 3, respectively).
A comparison of the TK gene sequences of all VZV isolates to that of the Dumas strain (the reference VZV strain for genotypic analyses) showed that each of the isolates had a substitution of S-288rL. This amino acid change has been found in nearly all VZV isolates described elsewhere by researchers other than Dumas [13, 15, 16, 19] . Only 3 patients (patients 1-3) with an SI 50 of у4 had an additional mutation in the TK gene (table 2) . The changes in the TK gene differed from those obtained from other patients: for each isolate, a unique mutation was found. Among these 3 VZV-resistant isolates, 2 substitutions (in patients 1 and 2) and 1 deletion (in patient 3) were detected in an area in which other mutation points have been described elsewhere.
DISCUSSION
Among the 11 patients with clinically suspected acyclovir-resistant VZV infection, only 3 (patients 1-3) had an acyclovirresistant VZV infection, as defined by both phenotypic and genetic characterization. For these 3 patients, it was noted that the SI 50 was у4. These results are in agreement with literature analyses that have shown that an SI 50 threshold of у4 may discriminate a resistant VZV strain from a susceptible one. In the present study, both IC 50 and SI 50 were used to characterize in vitro susceptibility, because IC 50 varies with the methods used and within the same method because of difficulties for standardization. The variation of IC 50 could be as large as 20-fold between 2 different methods for the same isolate, as was reported by Snoeck et al. [10] and Standing-Cox et al. [20] . Subsequently, we think that it is not always possible to deduct the susceptibility or the resistance of a VZV strain with nothing more than the IC 50 value. It was observed that the SI 50 results for all acyclovir-resistant strains of VZV were correlated with the drug-susceptibility status, no matter what method was used [7, 8, 10, [12] [13] [14] [15] .
For patient 2, the very terminal mutation point (substitution L332rP) can explain why the IC 50 and SI 50 are weakly increased. This mutation is located in an area that has already been implicated in acyclovir resistance by Boivin et al. [12] (strain 17 J), who reported a premature codon stop appearance at the amino acid 333 position near our mutation (amino acid 332). According to what is known about the herpes simplex virus TK, this terminal site on the TK is important for the enzyme stability [21] . With regard to this 6-year-old patient, it is noteworthy that the CD4 ϩ count was relatively high (290 cells/ mm 3 ), which stands in contrast with data published elsewhere [5, 7, 9, 11] and with data regarding 2 of our other patients (table 1) . However, because of maternofetal HIV transmission, we assume that this child had not established complete VZV immunity after his primary VZV infection. The severity of immunosuppression is an important risk factor for the occurrence of resistance to acyclovir. Thus, patient 1, who had additional factors of immunodepression, such as lymphoma, chemotherapy, and corticotherapy, exhibited the shortest delay (3 weeks with iv acyclovir) for the occurrence of acyclovir resistance.
Patient 3 was the only patient with a disseminated infection that began with a uniquely persistent and crusted lesion after healing of herpes zoster. The resulting mutation consisted of a truncated protein TK in which only 183 amino acids persisted among the 341 of the complete protein. Because of the large size of the deletion, it can be hypothesized that this deletion conferred a marked reduction of susceptibility to acyclovir (table 2).
These 3 patients (patients 1-3) died within 6 months of presentation, as had other patients reported elsewhere. Patient 3 died with the persistence of lesions after 1 month of treatment with foscarnet. Patients 1 and 2 were cured with foscarnet; however, they also died, without VZV recurrence 6 and 4 months after the lesions healed, respectively. Foscarnet, a drug with a metabolism not dependent on TK, is the main alternative therapy when acyclovir fails, and it cured 3 (60%) of 5 patients in the study by Safrin et al. [5] and 10 (70%) of 13 patients in the study by Breton et al. [11] .
We were surprised that, for the 7 other patients (patients 4-10) who were also selected because of persistent lesions after 10 days of acyclovir therapy, clinical resistance was not confirmed by virologic results. It is well known that clinical aspects of lesion caused by acyclovir-resistant VZV are often atypical-they are few, crusted, hyperkeratotic, and localized [1] . However, these aspects are not specific to antiviral resistance. Patients 4-10 had lesions that were undistinguished from those observed in patients with virologic resistance (patients 1-3) . Virologic resistance cannot be deducted on the basis of any clinical feature of the lesions. The chronic aspect seems to be supported by a particular pattern of VZV gE and gB gene expression [22] . Indeed, in our study, patients 4, 7, 8, and 10 had healing with the prolongation of acyclovir therapy, which is in accordance with our virologic results of acyclovir susceptibility. This clinical course suggests that the duration of the treatment needs to be increased to 110 days before the presence of an acyclovir-resistant VZV strain is suspected. In a study published elsewhere, patient 6 had been cured by use of sorivudine, a drug with a metabolism dependent on viral TK with an increased activity 2000-5000-fold greater than that of acyclovir [23] .
Patient 9 had an unusual profile of susceptibility. Although an SI 50 was !4, the IC 50 is high for a susceptible isolate; we hypothesize that this isolate is, in fact, a mixed population composed of both acyclovir-resistant and acyclovir-susceptible strains. The acyclovir-resistant strain is proportionally sufficient to increase the IC 50 , but it is in a proportion too weak to be sequenced on amplified products. The technique used allows detection of a double population only if the minor population is 120%.
If one takes into account patients 4-11, who had virologic acyclovir susceptibility, and patients 4, 7, 8, and 10 in particular, who simply required a longer time to heal with acyclovir, because the persistence of VZV infection was mainly the result of host deficiency, we suggest the introduction of the notion of "delay of healing." So, on one hand, it is necessary to continue acyclovir, a weakly toxic drug, with optimal dosage and for a longer period to allow the healing of such lesions, instead of switching to foscarnet, a highly toxic drug. On the other hand, treatment has to be switched early enough and prior to occurrence of an in vitro acyclovir-resistant VZV strain. No resistant strain was found in our study or in the literature in a delay shorter than 3 weeks. Subsequently, we suggest that the precedent definition of VZV acyclovir resistance, suspected after 10 days, should be modified, and that the duration of acyclovir treatment should be extended to 3 weeks before resistance is suspected. In vitro susceptibility should be determined at the same time to screen resistant isolates from sensitive ones.
